Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Needham initiated coverage on Axsome Therapeutics Inc (NASDAQ:AXSM), which focuses on central nervous disorders conditions, including depression, Alzheimer's disease agitation, migraine, narcolepsy, and fibromyalgia.
尼德姆開始報道Axsome Therapeutics Inc（納斯達克股票代碼：AXSM），該公司的重點是中樞神經疾病，包括抑鬱症、阿爾茨海默氏病躁動、偏頭痛、發作性睡病和纖維肌痛。
Needham writes that Axsome Therapeutics' diversified CNS portfolio will help grow the risk-adjusted topline by 8-10x in five years.
尼德姆寫道，Axsome Therapeutics的多元化中樞神經系統投資組合將有助於在五年內將風險調整後的收入增長8-10倍。
The analyst anticipates an upside for Axsome Therapeutics on its two marketed drugs, Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness.
該分析師預計，Axsome Therapeutics的兩種上市藥物都有上行空間，即治療重度抑鬱症的Auvelity和治療日間過度嗜睡的Sunosi。
Related: Axsome Depression Drug's Commercial Success, Pipeline Potential Undervalued, Analyst Says.
相關信息：分析師稱，Axsome抑鬱藥物的商業成功，管道潛力被低估。
Physicians report a positive experience with Auvelity due to its novel mechanism of action, rapid onset, and efficacy. However, they note that payer coverage could be better. Physicians were generally positive about increasing their use of Auvelity, but Needham does not anticipate better-than-expected growth for the drug.
醫生報告說，由於Auvelity具有新穎的作用機制、快速起效和療效，因此獲得了積極的使用體驗。但是，他們指出，付款人的覆蓋範圍可能會更好。醫生普遍對增加Auvelity的使用持樂觀態度，但Needham預計該藥物的增長不會好於預期。
Needham initiated with a Buy rating and a price target of $130.
Needham最初的評級爲買入，目標股價爲130美元。
The analyst says the company's most significant pipeline asset, AXS-05 in Alzheimer's Disease agitation, is already de-risked based on two positive Phase 3 trial data, and the ADVANCE-2 Ph 3 readout this year will support a filing.
該分析師表示，根據兩項積極的三期試驗數據，該公司最重要的管道資產，即用於阿爾茨海默氏病的 AXS-05，已經降低了風險，今年 ADVANCE-2 Ph 3 的讀數將爲申請提供支持。
Needham estimates 2028 US sales of ~$550 million (+11% vs. cons), growing to ~$1 billion in 2030
尼德姆估計，2028年美國的銷售額約爲5.5億美元（與缺點相比增長11％），到2030年將增長到約10億美元
Currently, Axsome receives no value for its remaining pipeline, but several of these products are in the late stages.
目前，Axsome的剩餘產品線沒有任何價值，但其中一些產品處於後期階段。
Needham anticipates they will contribute to topline growth soon.
Needham預計，他們將很快爲收入增長做出貢獻。
Axsome has three late-stage assets: AXS-07 for migraine, AXS-14 for fibromyalgia—2Q24 filing, and AXS-12 for narcolepsy filing post-second half data safety data, which can collectively drive ~$1 billion in sales by 2030 with a 60-65% probability of success.
Axsome擁有三項後期資產：用於偏頭痛的 AXS-07，用於纖維肌痛的 AXS-14 ——24年第二季度申報，以及用於發作性睡病提交下半年數據安全數據的 AXS-12，到2030年，總共可以推動約10億美元的銷售額，成功概率爲60-65％。
Price Action: AXSM stock is up 1.21% at $85.88 at the last check on Monday.
價格走勢：在週一的最後一次支票中，AxSM股價上漲1.21％，至85.88美元。
- Cassava Sciences Advances Alzheimer's Drug Through High-Stakes Phase 3 Trials.
- 木薯科學通過高風險的3期試驗推進阿爾茨海默氏症藥物的發展。